C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/70 (2006.01) A61P 31/18 (2006.01) C07H 21/04 (2006.01) C12Q 1/02 (2006.01) C12Q 1/68 (2006.01) G01N 33/569 (2006.01)
Patent
CA 2422489
This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly non-nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.
L'invention porte sur des essais de susceptibilité et se résistance à des médicaments antiviraux servant à identifier des posologies efficaces pour le traitement d'infections par le VIH, et du SIDA, dont en particulier des posologies incluant un inhibiteur de la transcriptase inverse. L'invention porte également sur des moyens et procédés de suivi de la progression de l'infection par le VIH, et de sa réponse à une thérapie antivirale, en particulier par un inhibiteur non nucléoside de la transcriptase inverse, dans le cadre d'essais de susceptibilité aux phénotypes et génotypes.
Osler Hoskin & Harcourt Llp
Virologic Inc.
LandOfFree
Non-nucleoside reverse transcriptase inhibitor as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-nucleoside reverse transcriptase inhibitor as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-nucleoside reverse transcriptase inhibitor as... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1502226